Merck & Co. Inc. / Ablynx NV

Solid Tumors (Cancer Immunotherapy via Immune Checkpoint Modulators)

Disease Overview

Immune checkpoint modulator targets (PD-1/PD-L1, CTLA-4, and emerging nodes such as TIM-3, LAG-3, TIGIT) underpin cancer immunotherapy across solid tumors. The 2014 deal aimed at multi-specific Nanobody constructs that could engage two or more checkpoint targets simultaneously — a differentiated approach versus monoclonal antibody monotherapy.

Competitive Landscape

In February 2014, the immuno-oncology checkpoint race was anchored by Bristol-Myers Squibb's Yervoy (anti-CTLA-4, approved 2011) and Opdivo (anti-PD-1, approved December 2014), Merck & Co.'s Keytruda (anti-PD-1, approved September 2014), and Roche/Genentech's atezolizumab (anti-PD-L1, then in late-stage development). Merck KGaA — distinct from US-based Merck & Co. — was attempting to enter the platform race with Pfizer-partnered avelumab (anti-PD-L1) and needed differentiated mechanisms to compete. Ablynx's Nanobody platform offered single-domain VHH fragments capable of bi- and tri-specific constructs targeting multiple checkpoints simultaneously — a structural advantage over conventional IgG. The €27M total upfront (€20M cash + €10.7M research funding) was modest, but the €1.7B biobucks across five programs reflected Merck KGaA's willingness to underwrite optionality. The deal was structurally similar to the parallel Ablynx-Merck & Co. (Sharp & Dohme) collaboration signed in 2015 worth up to $4.4B, which Jefferies analyst Peter Welford called 'reassuring progress' on the original immune-checkpoint candidates. Ablynx subsequently was acquired by Sanofi in January 2018 for €3.9B, validating the platform.